June 5 Company Quick Takes: Enzyvant's athymia candidate gets Priority review; plus Alnylam, Corbin and Institute Pasteur
Priority Review for Enzyvant's RVT-802
Enzyvant Sciences GmbH (Basel, Switzerland) said FDA accepted and granted Priority Review to a BLA for RVT-802 to treat pediatric congenital athymia. A decision is expected in December for the cultured, partially T cell-depleted, allogeneic thymic tissue for transplantation.
Alnylam completes NDA for hepatic porphyria candidate
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it completed a rolling NDA for givosiran to treat acute hepatic porphyria. The biotech expects to submit an MAA to EMA mid-year for the subcutaneous RNAi therapeutic targeting ALAS-1...